Case report reveals rapid progression of chronic lymphocytic leukemia after cemiplimab in a patient with cutaneous squamous cell carcinoma, suggesting careful monitoring is necessary.
Over the past decade, immune checkpoint inhibitors (ICIs) have revolutionized oncology care, resulting in sustained clinical remissions and prolonged overall survival. With this remarkable success comes the challenge of managing adverse events. We present a case of a patient with chronic lymphocytic leukemia (CLL) and cutaneous squamous cell carcinoma (cSCC) who received treatment for the advanced cSCC with Cemiplimab. This intervention led to a rapid progression of her hitherto quiescent CLL, and she began treatment for it. Understanding the complex mechanism of action of ICIs and the pathophysiology of lymphoid malignancies is important for the safe use of ICIs.
No takes yet. Share an insight, caveat, or question.
Fawole et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: